HLA-B*27:05 alters immunodominance hierarchy of universal influenza-specific CD8+ T cells.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
08 2020
Historique:
received: 09 04 2020
accepted: 18 06 2020
revised: 14 08 2020
pubmed: 5 8 2020
medline: 8 10 2020
entrez: 5 8 2020
Statut: epublish

Résumé

Seasonal influenza virus infections cause 290,000-650,000 deaths annually and severe morbidity in 3-5 million people. CD8+ T-cell responses towards virus-derived peptide/human leukocyte antigen (HLA) complexes provide the broadest cross-reactive immunity against human influenza viruses. Several universally-conserved CD8+ T-cell specificities that elicit prominent responses against human influenza A viruses (IAVs) have been identified. These include HLA-A*02:01-M158-66 (A2/M158), HLA-A*03:01-NP265-273, HLA-B*08:01-NP225-233, HLA-B*18:01-NP219-226, HLA-B*27:05-NP383-391 and HLA-B*57:01-NP199-207. The immunodominance hierarchies across these universal CD8+ T-cell epitopes were however unknown. Here, we probed immunodominance status of influenza-specific universal CD8+ T-cells in HLA-I heterozygote individuals expressing two or more universal HLAs for IAV. We found that while CD8+ T-cell responses directed towards A2/M158 were generally immunodominant, A2/M158+CD8+ T-cells were markedly diminished (subdominant) in HLA-A*02:01/B*27:05-expressing donors following ex vivo and in vitro analyses. A2/M158+CD8+ T-cells in non-HLA-B*27:05 individuals were immunodominant, contained optimal public TRBV19/TRAV27 TCRαβ clonotypes and displayed highly polyfunctional and proliferative capacity, while A2/M158+CD8+ T cells in HLA-B*27:05-expressing donors were subdominant, with largely distinct TCRαβ clonotypes and consequently markedly reduced avidity, proliferative and polyfunctional efficacy. Our data illustrate altered immunodominance patterns and immunodomination within human influenza-specific CD8+ T-cells. Accordingly, our work highlights the importance of understanding immunodominance hierarchies within individual donors across a spectrum of prominent virus-specific CD8+ T-cell specificities prior to designing T cell-directed vaccines and immunotherapies, for influenza and other infectious diseases.

Identifiants

pubmed: 32750095
doi: 10.1371/journal.ppat.1008714
pii: PPATHOGENS-D-20-00714
pmc: PMC7428290
doi:

Substances chimiques

Epitopes, T-Lymphocyte 0
HLA-B*27:05 antigen 0
HLA-B27 Antigen 0
Immunodominant Epitopes 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008714

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Immunol Cell Biol. 2017 Jan;95(1):68-76
pubmed: 27670790
Clin Exp Immunol. 2010 Mar;159(3):245-55
pubmed: 19968665
J Gen Virol. 2013 Mar;94(Pt 3):583-592
pubmed: 23152369
Nat Commun. 2019 Dec 6;10(1):5579
pubmed: 31811120
J Immunol. 2004 Apr 1;172(7):4435-43
pubmed: 15034059
Annu Rev Immunol. 2003;21:29-70
pubmed: 12414723
J Virol. 2007 Nov;81(22):12382-93
pubmed: 17804494
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4440-5
pubmed: 27036003
Immunol Cell Biol. 2013 Feb;91(2):184-94
pubmed: 23399741
Nature. 2017 Dec 21;552(7685):362-367
pubmed: 29236685
Immunol Cell Biol. 2017 Jan;95(1):77-86
pubmed: 27507557
J Immunol. 2009 Jun 1;182(11):6718-26
pubmed: 19454666
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9178-83
pubmed: 21562214
Tissue Antigens. 2003 May;61(5):403-7
pubmed: 12753660
J Virol. 2008 Dec;82(24):12241-51
pubmed: 18842709
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4102-7
pubmed: 8633023
Sci Transl Med. 2018 Feb 14;10(428):
pubmed: 29444980
Hepatology. 2010 Jan;51(1):54-62
pubmed: 20034048
Immunity. 2006 Oct;25(4):533-43
pubmed: 17046682
PLoS Pathog. 2012 Feb;8(2):e1002544
pubmed: 22383879
N Engl J Med. 2009 Nov 12;361(20):1945-52
pubmed: 19745214
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Annu Rev Immunol. 1993;11:403-50
pubmed: 8476568
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
J Virol. 2008 Jun;82(11):5161-6
pubmed: 18353950
Clin Infect Dis. 2011 Jan 1;52(1):1-7
pubmed: 21148512
Nat Med. 2013 Oct;19(10):1305-12
pubmed: 24056771
Nat Commun. 2015 May 13;6:6833
pubmed: 25967273
Oncoimmunology. 2013 Nov 1;2(11):e26840
pubmed: 24482751
Nat Immunol. 2003 Jul;4(7):657-63
pubmed: 12796775
Eur J Immunol. 2009 Aug;39(8):2076-82
pubmed: 19672903
Clin Immunol. 2012 May;143(2):99-115
pubmed: 22391152
Nat Immunol. 2002 Nov;3(11):1061-8
pubmed: 12368910
PLoS Med. 2006 Oct;3(10):e403
pubmed: 17076553
Front Immunol. 2018 Jun 27;9:1453
pubmed: 29997621
J Clin Invest. 2008 Oct;118(10):3478-90
pubmed: 18802496
Nat Immunol. 2019 May;20(5):613-625
pubmed: 30778243
Nat Med. 2007 Jul;13(7):843-50
pubmed: 17558415
J Virol. 2014 Feb;88(3):1684-93
pubmed: 24257602
Front Immunol. 2018 Feb 16;9:276
pubmed: 29503649
Expert Opin Biol Ther. 2009 Jan;9(1):55-69
pubmed: 19063693
J Infect Dis. 2020 Aug 4;222(5):807-819
pubmed: 31740938
Immunity. 2009 Feb 20;30(2):193-203
pubmed: 19167249
J Exp Med. 2007 Oct 1;204(10):2473-85
pubmed: 17893201
Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12599-604
pubmed: 20616031
J Exp Med. 2007 Jun 11;204(6):1405-16
pubmed: 17535971
J Exp Med. 2005 Nov 21;202(10):1349-61
pubmed: 16287711
Clin Transl Immunology. 2017 Mar 17;6(3):e134
pubmed: 28435676
Curr Opin Rheumatol. 2013 Jul;25(4):426-33
pubmed: 23656712
Annu Rev Immunol. 2000;18:275-308
pubmed: 10837060
Nature. 2017 Dec 21;552(7685):404-409
pubmed: 29236683
Curr Opin Immunol. 2015 Jun;34:43-51
pubmed: 25660347
J Immunol. 2012 Jan 1;188(1):311-21
pubmed: 22140258
Vaccine. 2012 Jun 29;30(31):4655-60
pubmed: 22575166
J Virol. 2003 Jun;77(12):6889-98
pubmed: 12768008
J Virol. 2015 Apr;89(8):4102-16
pubmed: 25609818
Blood. 2009 Jun 18;113(25):6351-60
pubmed: 19389882
Immunol Cell Biol. 2010 Aug;88(6):676-84
pubmed: 20195281
Nat Commun. 2018 Dec 21;9(1):5427
pubmed: 30575715
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1049-54
pubmed: 24395804
Nat Commun. 2013;4:2663
pubmed: 24173108
PLoS One. 2013 May 03;8(5):e62778
pubmed: 23658773
J Clin Invest. 2016 Jun 1;126(6):2093-108
pubmed: 27111229
AIDS. 2003 Dec 5;17(18):2581-91
pubmed: 14685052
J Leukoc Biol. 2018 Feb;103(2):321-339
pubmed: 28928269

Auteurs

Sneha Sant (S)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Sergio M Quiñones-Parra (SM)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Marios Koutsakos (M)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Emma J Grant (EJ)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Thomas Loudovaris (T)

Immunology and Diabetes Unit, St Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.

Stuart I Mannering (SI)

Immunology and Diabetes Unit, St Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.

Jane Crowe (J)

Deepdene Surgery, Deepdene, Victoria, Australia.

Carolien E van de Sandt (CE)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Guus F Rimmelzwaan (GF)

National Influenza Center and Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.

Jamie Rossjohn (J)

Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia.
Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom.

Stephanie Gras (S)

Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia.

Liyen Loh (L)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Thi H O Nguyen (THO)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Katherine Kedzierska (K)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH